ANTARES: Agnostic Therapy in Rare Solid Tumors (clinicaltrials.gov) - Oct 14, 2026 - P2 | N=28 | Active, not recruiting | Sponsor: Instituto do Cancer do Estado de São Paulo | Trial primary completion date: Jul 2026 ➔ Jul 2027 | Recruiting ➔ Active, not recruiting
Enrollment closed • IO biomarker • Trial primary completion date • Adenoid Cystic Carcinoma • Anal Carcinoma • Angiosarcoma • Biliary Cancer • Brain Cancer • Breast Cancer • Carcinosarcoma • Cholangiocarcinoma • Embryonal Tumor • Endometrial Cancer • Fallopian Tube Cancer • Fibrosarcoma • Gallbladder Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Hepatoblastoma • Hepatocellular Cancer • Hormone Receptor Positive Breast Cancer • Kaposi Sarcoma • Leiomyosarcoma • Mesothelioma • Neuroblastoma • Neuroendocrine Tumor • Neurofibrosarcoma • Oncology • Osteosarcoma • Ovarian Cancer • Penile Cancer • Renal Cell Carcinoma • Sarcoma • Small Intestinal Carcinoma • Soft Tissue Sarcoma • Solid Tumor • Thyroid Gland Carcinoma • Urethral Cancer • Vaginal Cancer • Vulvar Cancer
|